Primary Recipient

DANA-FARBER CANCER INSTITUTE, INC.

Amount

$1,817,442.00

Award Date

9/28/2009

Administering Agency

Health and Human Services, Department of / National Institutes of Health

CDFA Number

93.701

CDFA Program Title

Trans-NIH Recovery Act Research Support

Description

This stage one TRIP application will enable a phase II clinical trial of a new therapy to treat sickle cell disease (SCD) in two years. The basis of our proposal is our recent discovery that invariant NKT (iNKT) cells contribute importantly to tissue infl

Recipients Connected to Award

Recipient	Role	Amount
LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY	Sub-recipient	$566,581.00
DANA-FARBER CANCER INSTITUTE, INC.	Primary recipient	$517,764.00
BRIGHAM AND WOMEN'S HOSPITAL, INC., THE	Sub-recipient	$260,981.00
WASHINGTON UNIVERSITY, THE	Sub-recipient	$241,832.00
BETH ISRAEL DEACONESS MEDICAL CENTER INC	Sub-recipient	$173,714.00
CHILDREN'S HOSPITAL CORPORATION, THE	Sub-recipient	$40,750.00
JOHNS HOPKINS UNIVERSITY, THE	Sub-recipient	$15,820.00